BridgeBio Pharma, Inc. business relationships

Companies named in BridgeBio Pharma, Inc.’s 10-K filed 2026-02-24, and public companies whose annual reports name BridgeBio Pharma, Inc.. Each link shows the sentence it came from. Scores are Engagemii’s AI visibility scores.

Open on the map Full AI visibility profile

AEO visibility: 6.1 / 10
AI naming: 100 / 100
Agent readiness: 30 / 100
AI adoption: 0 / 100

Named in BridgeBio Pharma, Inc.’s annual report 7

NOVARTIS AG (NVS)Licensee7.7
“We also have certain rights to intellectual property licensed to Novartis' affiliate under a materials transfer agreement with a third party.” SEC filing
BayerLicensor7.7
“License Agreement with Bayer” SEC filing
NOVARTIS AG (NVS)Licensor7.7
“License Agreement with Novartis International Pharmaceutical Ltd.” SEC filing
BayerPartner7.7
“In 2026, we plan to continue our collaborations with Bayer and Alexion to drive continued growth in Europe and Japan, respectively.” SEC filing
BayerSupplier7.7
“Similarly, those services provide a distinct benefit to Bayer within the context of the contract, separate from the license, as the services could be provided by Bayer or another third-party without our assistance.” SEC filing
AlexionPartner6.1
“• the potential failure of obtaining and maintaining required licenses with foreign regulatory authorities that are required to ship API or distribute our drug product to customers or commercial partners like Bayer and Alexion;” SEC filing
Kyowa Kirin Co., Ltd.Partner6.1
“On February 7, 2024, the Company's subsidiary, QED, and Kyowa Kirin Co., Ltd ("Kyowa Kirin" or "KKC") entered into a license and collaboration agreement pursuant to which QED granted Kyowa Kirin an exclusive license to develop, manufacture, and commercialize infigratinib for achondroplasia, hypochon...” SEC filing

Links are read automatically from SEC annual reports (10-K, 20-F, 40-F). In a hand check of random links, about 8 in 10 were real business relationships, so every link carries its source sentence.